Communiqués Amarin Corporation plc

Actions

AMRN

US0231114044

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/06/2026			Varia. 5j.	Varia. 1 janv.
15,91 ^USD	-2,69 %		-0,75 %	+14,01 %

23/06	Principales affaires inscrites au rôle de la Cour suprême des États-Unis	RE
22/06	Les actions européennes cotées aux États-Unis sous forme d'ADR progressent lors de la séance de lundi	MT

Communiqués

27/05	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia	AQ
29/04	Amarin: Q1 Earnings Snapshot	AQ
29/04	Amarin Reports 2026 First Quarter Financial Results	AQ
15/04	Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026	AQ
08/04	American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction	AQ
18/03	Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline	AQ
16/03	New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo	AQ
02/03	Amarin : Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT...	PU
02/03	Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology	AQ
25/02	Amarin: Q4 Earnings Snapshot	AQ
25/02	Amarin Reports Fourth Quarter and Full Year 2025 Financial Results	AQ
23/02	This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease	AQ
11/02	Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026	AQ
09/01	Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization	AQ
08/01	Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities	AQ
07/01	Lotus Pharmaceutical Secures First Southeast Asian Approval for VAZKEPA in Singapore	AQ
09/11	New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients	AQ
03/11	Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025	AQ
29/10/25	Amarin: Q3 Earnings Snapshot	AQ
29/10/25	Amarin Reports Third Quarter 2025 Financial Results	AQ
28/10/25	Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit	AQ
27/10/25	Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit	AQ
15/10/25	Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025	AQ
14/10/25	Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress	AQ
19/09/25	Amarin : Corporate Overview	PU